	US 11,746,339 B2
	Modified DNA polymerases for improved amplification
Wolfgang Schafer, Western Cape (ZA); Paul J. McEwan, Diablo, CA (US); Eric van der Walt, Western Cape (ZA); John Foskett, Boulder, CO (US); and William Bourn, Western Cape (CA)
Assigned to Kapa Biosystems, Inc., Wilmington, MA (US)
Filed by Kapa Biosystems, Inc., Wilmington, MA (US)
Filed on Mar. 11, 2021, as Appl. No. 17/199,343.
Application 17/199,343 is a continuation of application No. 15/130,339, filed on Apr. 15, 2016, granted, now 10,975,361.
Application 15/130,339 is a continuation of application No. 13/979,509, granted, now 9,315,787, issued on Apr. 19, 2016, previously published as PCT/US2012/021348, filed on Jan. 13, 2012.
Claims priority of provisional application 61/432,936, filed on Jan. 14, 2011.
Prior Publication US 2021/0317422 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/12 (2006.01); C12P 19/34 (2006.01); C12Q 1/686 (2018.01)

CPC C12N 9/1252 (2013.01) [C12P 19/34 (2013.01); C12Q 1/686 (2013.01); C12Y 207/07007 (2013.01); Y02P 20/52 (2015.11)]

11 Claims

1. A kit comprising:

(i) a package unit with a container comprising a modified Taq DNA polymerase whose amino acid sequence shares at least 95% identity with that of SEQ ID NO: 48, including in that it has L at a position corresponding to F749 of a reference Taq DNA polymerase of SEQ ID NO: 38, and in that it has at least two other amino acid substitutions at positions relative SEQ ID NO: 38, which substitutions are selected from the group consisting of T at 61, E at 346, C at 357, K at 507, M at 707 and combinations thereof; and

(ii) instructions.